Acute liver failure arising in the context of cytomegalovirus (CMV) hepatitis represents a serious condition in which active CMV infection drives rapid hepatic deterioration, requiring prompt, targeted intervention.
The evidence-based approach centres on directed intravenous antiviral therapy. The complete regimen — including specific agent, dosing, duration, and monitoring parameters — is contained in the full structured protocol.
DOI: 10.14309/ajg.0000000000002340
IV ganciclovir is recommended for the treatment of CMV hepatitis.
View source ↗